Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.75
Bid: 10.50
Ask: 11.00
Change: 0.00 (0.00%)
Spread: 0.50 (4.762%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 10.75
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sareum flags potentially significant findings for SRA737

Thu, 28th Feb 2019 14:33

(Sharecast News) - Specialist small molecule drug development company Sareum Holdings announced on Thursday that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, had reported that an abstract reporting preclinical data for SRA737 - its Chk1 inhibitor - plus low dose gemcitabine (LDG), in combination with immunotherapy, had been selected for a late-breaking oral presentation at the American Association of Cancer Research annual meeting.The AIM-traded firm said SRA737 - its leading clinical-stage programme - was a "novel" Checkpoint kinase 1 (Chk1) inhibitor, was licensed to NASDAQ-listed Sierra Oncology, and was in Phase 2 clinical trials targeting ovarian and other advanced cancers.It explained that a late-breaking abstract detailed "highly significant and timely" findings in any area of cancer research that was not available at the time of the regular abstract deadline.Only those abstracts that were deemed to be of "high scientific priority" would be accepted for presentation at the meeting."We previously reported that SRA737 activated the innate immune signalling STING pathway and demonstrated significant synergistic anti-tumour activity with immunotherapy in an immunotherapy-refractory small cell lung cancer (SCLC) model," said Dr Lauren Byers, associated professor at the University of Texas MD Anderson Cancer Center in Houston."SRA737 + LDG is a novel drug combination, where gemcitabine acts as a potent inducer of replication stress that potentiates SRA737's activity."Dr Byers said the new studies revealed a "striking" immunomodulatory effect of SRA737 + LDG, that resulted in "some of the most profound" synergistic activity with anti-PD-L1 therapy that they had observed in the model."We are excited by the potential clinical translatability of these findings and their possible broader impact on immune checkpoint blockade strategies."Dr Christian Hassig, chief scientific officer at Sierra Oncology, added that the "dramatic enhancement" of immunotherapy anti-tumour activity in combination with SRA737 + LDG provided a "strong preclinical rationale" for the potential of that replication stress targeting strategy, to broaden the limited clinical efficacy of immunotherapy observed in certain cancers, such as SCLC.
More News
28 Mar 2024 13:44

EARNINGS AND TRADING: Northamber loss widens; Ethernity contract boost

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
15 Mar 2024 13:11

Sareum allowed European patent for primary kinase inhibitor asset

(Sharecast News) - Biotechnology company Sareum announced on Friday that the European Patent Office had issued a notice of allowance for a patent concerning SDC‐1801, its primary TYK2/JAK1 kinase inhibitor currently undergoing clinical trials in Australia.

Read more
15 Mar 2024 12:46

Sareum Holdings touts new patent allowance for autoimmune therapy

(Alliance News) - Sareum Holdings PLC on Friday celebrated a new patent allowance for SDC-1801, which is a therapy designed to treat a range of autoimmune diseases.

Read more
12 Mar 2024 15:23

Sareum shares slump on widened loss and funding talks

(Alliance News) - Sareum Holdings PLC share fell on Tuesday, after it said it expects to report a widened interim loss.

Read more
15 Feb 2024 13:22

Sareum reports positive progress in psoriasis programme

(Sharecast News) - Sareum announced significant milestones in its phase 1a clinical trial for SDC-1801, its lead programme aimed at addressing autoimmune diseases such as psoriasis, on Thursday.

Read more
15 Feb 2024 11:20

Sareum hails safety profile for SDC-1801 after phase 1 trial

(Alliance News) - Sareum Holdings PLC on Thursday said SDC-1801 has the potential to achieve therapeutically effective dose levels with no serious adverse events, following a phase 1 trial.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
2 Jan 2024 13:54

Sareum shares jump on cancer drug licensing deal

(Sharecast News) - Shares in AIM-listed biotech group Sareum jumped by a fifth on Tuesday after its co-development partner for cancer treatment SRA737 signed a commercialisation licence agreement with a US biopharma company.

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 10:05

AIM WINNERS & LOSERS: LungLife AI soars on test; Plexus falls on deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
2 Jan 2024 09:31

Sareum soars as partner agrees SRA737 licence with US biopharma firm

(Alliance News) - Sareum Holdings PLC shares surged on Tuesday, after it said its co-development partner CRT Pioneer Fund entered into a development and commercialisation licence for SRA737 with an unnamed US biopharmaceutical company.

Read more
14 Dec 2023 20:20

EARNINGS AND TRADING: CleanTech raises GBP520,000 in open offer

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
7 Dec 2023 14:31

UK shareholder meetings calendar - next 7 days

Friday 8 December 
Amedeo Air Four Plus LtdAGM
Ashoka India Equity Investment Trust PLCAGM
Associated British Engineering PLCAGM
Associated British Foods PLCAGM
Corcel PLCGM re disposal of 41% interest in the Mambare nickel/cobalt project
Hargreaves Lansdown PLCAGM
URA Holdings PLCGM re closing the fundraise
Monday 11 December 
IamFire PLCAGM with vote on name change to WeCap PLC
Pharma C Investments PLCGM re allowing investments in fintech, AI sectors
SigmaRoc PLCGM re reverse takeover
Tribal Group PLCGM re cash offer by Tiger Bidco 1 Ltd
Vela Technologies PLCAGM
Tuesday 12 December 
Atalaya Mining PLCEGM re redomiciliation to Spain from Cyprus
Blackrock Greater Europe Investment Trust PLCAGM
Distil PLCGM re placing and subscription
Gelion PLCAGM
Wednesday 13 December 
Dechra Pharmaceuticals PLCAGM
Limitless Earth PLCAGM
Softcat PLCAGM
Volution Group PLCAGM
Thursday 14 December 
Aeorema Communications PLCAGM
CleanTech Lithium PLCGM re equity raise approval
Driver Group PLCFull Year Results
eEnergy Group PLCAGM
Ethernity Networks LtdGM re authority to allot shares on non-preemptive basis
Fintech Asia LtdAGM
Helium One Global LtdAGM
Marwyn Value Investors LtdAGM
Quarto Group IncGM re cancelling trading on London's Main Market
Sareum Holdings PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
23 Nov 2023 14:28

IN BRIEF: Sareum Holdings draws down on equity prepayment facility

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company, focused on developing kinase inhibitors to treat autoimmune diseases and cancer - Says that it has drawn down on the GBP300,000 second deposit in respect of a previously announced equity prepayment facility.

Read more
9 Nov 2023 13:47

EARNINGS AND TRADING: MetalNRG hails Gold Ridge findings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.